Artiva Biotherapeutics, Inc. (ARTV)

In the past six months, Artiva Biotherapeutics' stock has experienced significant movement. On May 8, 2026, Artiva announced the pricing of a $300 million underwritten public offering and reported its first-quarter 2026 financial results, with a net loss of $23.5 million, or $0.95 per share, which was wider than analysts' expectations. Also on May 8, 2026, Artiva announced positive initial clinical data for AlloNK® in refractory rheumatoid arthritis (RA) and received FDA alignment to initiate a Phase 3 registrational trial in RA in 2026. On March 10, 2026, the company reported full-year 2025 financial results and highlighted progress in its AlloNK program. On October 17, 2025, Artiva Biotherapeutics received FDA Fast Track designation for its first-in-class B-cell depleting therapy in refractory RA.

Artiva Biotherapeutics, Inc. does not currently have commercialized products or services subject to demand seasonality. The company's revenue generation is primarily tied to research and development milestones, collaborations, and financing activities rather than seasonal consumer demand.

Artiva Biotherapeutics, Inc. (ARTV) is a clinical-stage biopharmaceutical company focused on developing off-the-shelf, allogeneic natural killer (NK) cell-based therapies for autoimmune diseases and cancers. Their lead product candidate, AlloNK®, is being evaluated in clinical trials for various autoimmune diseases and B-cell non-Hodgkin lymphoma. The company's pipeline also includes CAR-NK cell candidates AB-201 and AB-205 for solid tumors and hematological malignancies, respectively.

Artiva Biotherapeutics, Inc. is headquartered in San Diego, California, with R&D and GMP manufacturing facilities. They also utilize research and cGMP manufacturing capabilities through their partner, GC Cell, in the Republic of Korea.

Artiva Biotherapeutics' brand reputation has been positively influenced by clinical advancements, including positive initial clinical data for AlloNK® in refractory rheumatoid arthritis and FDA alignment for a Phase 3 trial. The FDA Fast Track designation for its B-cell depleting therapy in refractory RA in October 2025 further bolstered its reputation. While the recent discounted public offering and a wider-than-expected Q1 loss led to some stock price volatility, the underlying positive clinical news and regulatory progress contribute to a generally favorable brand perception.

Artiva Biotherapeutics, Inc. has a significant institutional ownership presence, with 37 institutional owners and shareholders holding a total of 17,009,352 shares as of May 1, 2026. Major institutional shareholders include RA Capital Management, L.P., 5AM Venture Management, LLC, VR Adviser, LLC, venBio Partners LLC, Franklin Resources Inc, Revelation Capital Management, LLC, Vanguard Group Inc, Millennium Management Llc, BlackRock, Inc., and Wellington Management Group Llp.